Hospital
Prospect Chartercare Sjhsri, LLC
Prospect Chartercare Sjhsri, LLC was paid $10.94M by Medicaid between Jan 2018 and Dec 2024, across 208 billing codes. Its largest line is 99283, emergency room visit (moderate) — 7.4% of everything it billed.
33Billing provider infoPROSPECT CHARTERCARE SJHSRI, LLC
NORTH PROVIDENCE, RI 02904
NORTH PROVIDENCE, RI 02904
33aNPI1871918870assigned 02/27/2014
33bProvider typeGeneral Acute Care Hospital
28Total paid$10.94M
24GClaims293,481
24DCodes billed208
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Rhode Island
Rank by total paid#7 of 11
Median peer was paid$12.56M
This provider vs. median0.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ELDERS, ROBERT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 110,827 | $3.42M | |
| 2019 | 123,201 | $5.78M | |
| 2020 | 14,341 | $498K | |
| 2021 | 11,889 | $310K | |
| 2022 | 12,462 | $286K | |
| 2023 | 12,641 | $407K | |
| 2024incomplete | 8,120 | $230K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 7.4% | 3,716 | 2,406 | $804K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.8% | 23,108 | 16,630 | $524K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.2% | 1,390 | 997 | $457K |
| 36415 | Collection of venous blood by venipuncture | 4.0% | 12,061 | 9,671 | $442K |
| 80061 | Lipid panel | 3.6% | 15,068 | 11,256 | $394K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.3% | 9,509 | 6,909 | $365K |
| 84443 | Thyroid stimulating hormone (TSH) | 3.3% | 14,377 | 10,297 | $362K |
| 80053 | Comprehensive metabolic panel | 3.1% | 17,118 | 12,389 | $343K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.6% | 9,198 | 6,877 | $289K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 1,123 | 604 | $286K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 2.6% | 4,271 | 3,901 | $284K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.4% | 5,260 | 3,354 | $264K |
196 more codes
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.3% | 5,115 | $253K |
| 87660 | 2.2% | 2,142 | $245K | |
| 99284 | Emergency room visit (serious) | 2.2% | 1,490 | $242K |
| 81001 | 1.9% | 12,821 | $212K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.4% | 4,050 | $153K |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.4% | 9,898 | $149K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.4% | 1,299 | $149K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.2% | 1,096 | $132K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.2% | 978 | $132K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.1% | 8,663 | $125K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.1% | 1,737 | $121K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.1% | 1,252 | $117K |
| 80076 | 1.0% | 3,329 | $111K | |
| 82962 | 1.0% | 2,297 | $109K | |
| 82607 | <1% | 4,841 | $107K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,636 | $103K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,077 | $99K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,321 | $89K |
| 86141 | <1% | 1,230 | $86K | |
| 85027 | <1% | 4,110 | $86K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 416 | $84K |
| 84484 | <1% | 1,277 | $81K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,020 | $81K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 497 | $74K |
| 82728 | <1% | 3,422 | $74K | |
| 83690 | <1% | 1,667 | $71K | |
| 87480 | <1% | 2,143 | $64K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 458 | $64K |
| 83735 | <1% | 1,345 | $61K | |
| 87510 | <1% | 2,064 | $61K | |
| 84439 | <1% | 4,101 | $60K | |
| 83880 | <1% | 507 | $59K | |
| 86803 | <1% | 2,847 | $59K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 987 | $54K |
| G0378 | Hospital observation service, per hour | <1% | 226 | $54K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 693 | $53K |
| 84466 | <1% | 2,502 | $52K | |
| 80050 | General health panel | <1% | 582 | $52K |
| 87186 | <1% | 2,449 | $50K | |
| 85610 | <1% | 2,529 | $50K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 594 | $49K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 528 | $48K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 971 | $47K |
| 82550 | <1% | 2,313 | $47K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 418 | $46K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 498 | $46K |
| 80074 | <1% | 695 | $45K | |
| J3490 | Unclassified drugs | <1% | 608 | $45K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 494 | $45K |
| 82565 | <1% | 1,202 | $45K | |
| 82043 | <1% | 3,881 | $44K | |
| 87081 | <1% | 2,195 | $43K | |
| 83540 | <1% | 3,306 | $42K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 432 | $41K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 398 | $40K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 540 | $39K |
| 81025 | <1% | 707 | $36K | |
| 87070 | <1% | 1,087 | $34K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 13 | $34K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,346 | $32K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 300 | $30K |
| 84520 | <1% | 687 | $30K | |
| 86706 | <1% | 1,849 | $30K | |
| 85652 | <1% | 3,262 | $30K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 370 | $29K |
| 87205 | <1% | 902 | $27K | |
| 82947 | <1% | 902 | $27K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 499 | $27K |
| 97162 | <1% | 293 | $27K | |
| 82746 | <1% | 1,580 | $26K | |
| 87077 | <1% | 1,230 | $26K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 2,725 | $25K |
| 80051 | <1% | 522 | $25K | |
| 86618 | <1% | 1,066 | $25K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,895 | $24K |
| 87340 | <1% | 1,509 | $24K | |
| 86900 | <1% | 593 | $24K | |
| 86901 | <1% | 593 | $23K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 110 | $23K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 94 | $23K |
| 97597 | <1% | 168 | $22K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 490 | $22K |
| 86850 | <1% | 565 | $22K | |
| 84154 | <1% | 924 | $22K | |
| 86592 | <1% | 2,210 | $20K | |
| 84460 | <1% | 2,313 | $19K | |
| 86038 | <1% | 1,000 | $18K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 1,444 | $18K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 377 | $17K |
| 83013 | <1% | 201 | $17K | |
| 88142 | <1% | 1,203 | $16K | |
| 86696 | <1% | 608 | $15K | |
| 85730 | <1% | 761 | $15K | |
| 97035 | <1% | 745 | $14K | |
| 84100 | <1% | 341 | $13K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 140 | $13K |
| 84450 | <1% | 1,517 | $12K | |
| 86694 | <1% | 560 | $12K | |
| 86695 | <1% | 608 | $12K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 393 | $11K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 175 | $11K |
| 86762 | <1% | 525 | $10K | |
| 83605 | <1% | 38 | $10K | |
| 84703 | <1% | 346 | $10K | |
| 84550 | <1% | 950 | $10K | |
| 84480 | <1% | 512 | $9K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 128 | $9K |
| 84702 | <1% | 336 | $9K | |
| 82150 | <1% | 858 | $9K | |
| 83721 | <1% | 373 | $8K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 81 | $8K |
| 86787 | <1% | 441 | $8K | |
| 84403 | <1% | 227 | $7K | |
| 86704 | <1% | 407 | $7K | |
| 84153 | <1% | 311 | $7K | |
| 86765 | <1% | 377 | $7K | |
| 86735 | <1% | 373 | $7K | |
| 84145 | <1% | 22 | $7K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 38 | $7K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 80 | $7K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 53 | $7K |
| 86431 | <1% | 669 | $6K | |
| 85379 | <1% | 201 | $6K | |
| 83655 | <1% | 830 | $6K | |
| 82553 | <1% | 284 | $5K | |
| 84436 | <1% | 551 | $5K | |
| 88342 | <1% | 82 | $5K | |
| 82274 | <1% | 81 | $5K | |
| 86780 | <1% | 196 | $5K | |
| 86665 | <1% | 201 | $5K | |
| 84270 | <1% | 161 | $5K | |
| 97167 | <1% | 72 | $5K | |
| 84207 | <1% | 146 | $5K | |
| 84146 | <1% | 134 | $4K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 48 | $4K |
| 83516 | <1% | 217 | $4K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 119 | $4K |
| 84252 | <1% | 142 | $4K | |
| 86617 | <1% | 160 | $3K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 30 | $3K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 41 | $3K |
| 86705 | <1% | 192 | $3K | |
| 92551 | <1% | 248 | $3K | |
| 82040 | <1% | 363 | $3K | |
| 84132 | <1% | 280 | $3K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 33 | $3K |
| 83970 | <1% | 71 | $3K | |
| 88112 | <1% | 17 | $2K | |
| 73030 | <1% | 44 | $2K | |
| 96127 | <1% | 196 | $2K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 43 | $2K |
| 85018 | <1% | 72 | $2K | |
| 84425 | <1% | 211 | $2K | |
| 71045 | Radiologic examination, chest; single view | <1% | 21 | $2K |
| 82977 | <1% | 201 | $2K | |
| 86664 | <1% | 106 | $2K | |
| 84481 | <1% | 239 | $2K | |
| 85045 | <1% | 305 | $2K | |
| 72100 | <1% | 55 | $2K | |
| 76642 | <1% | 29 | $2K | |
| S5000 | Prescription drug, generic | <1% | 49 | $2K |
| 86663 | <1% | 106 | $2K | |
| 82465 | <1% | 202 | $2K | |
| 83525 | <1% | 93 | $1K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 21 | $1K |
| 84402 | <1% | 45 | $1K | |
| 82248 | <1% | 80 | $1K | |
| 97163 | <1% | 13 | $1K | |
| 87430 | <1% | 63 | $1K | |
| 86800 | <1% | 53 | $1K | |
| 86480 | <1% | 23 | $1K | |
| 86677 | <1% | 59 | $1K | |
| 86376 | <1% | 50 | $1K | |
| 83718 | <1% | 105 | $1K | |
| 81002 | <1% | 159 | $1K | |
| 86738 | <1% | 71 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 19 | $896.10 |
| 84590 | <1% | 53 | $890.46 | |
| 87522 | Neg quan hep c or qual rna | <1% | 18 | $853.85 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 28 | $850.60 |
| 85014 | <1% | 46 | $785.84 | |
| 83001 | <1% | 30 | $721.08 | |
| 84075 | <1% | 54 | $670.01 | |
| 80164 | <1% | 38 | $621.02 | |
| 83615 | <1% | 18 | $512.03 | |
| 82670 | <1% | 12 | $428.64 | |
| 83520 | <1% | 12 | $390.81 | |
| 83002 | <1% | 16 | $379.04 | |
| 93000 | <1% | 14 | $358.40 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 22 | $327.85 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 13 | $234.67 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 12 | $199.56 |
| 86200 | <1% | 12 | $168.84 | |
| 82270 | <1% | 13 | $27.41 | |
| 90686 | <1% | 16 | $19.24 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialELDERS, ROBERT (SECRETARY)
| Provider | Location | Paid |
|---|---|---|
| Prospect Waterbury, INC. | Waterbury, CT | $84.62M |
| Prospect Manchester Hospital, INC. | Manchester, CT | $69.20M |
| Prospect Chartercare RWMC, LLC | Providence, RI | $57.10M |
| Prospect CCMC, LLC | Chester, PA | $40.89M |
| Prospect CT Medical Foundation, INC. | Manchester, CT | $34.07M |
| Prospect Rockville Hospital, INC. | Vernon, CT | $30.06M |
| Prospect DCMH, LLC | Drexel Hill, PA | $10.37M |
| Prospect CCMC, LLC | Chester, PA | $5.46M |
| Alta Los Angeles Hospitals, INC. | Los Angeles, CA | $5.42M |
| Prospect CCMC, LLC | Chester, PA | $5.03M |
| Prospect CCMC, LLC | Chester, PA | $3.71M |
| Prospect Chartercare Physicians, LLC | Cranston, RI | $2.31M |
| Prospect Echn Home Health, INC. | Vernon, CT | $1.75M |
| Prospect Waterbury Home Health, INC. | Watertown, CT | $1.30M |
| Prospect Health Access Network, INC. | Chester, PA | $1.22M |
| Alta Newport Hospital, LLC | Tustin, CA | $1.16M |
| Prospect Health Access Network, INC. | Crum Lynne, PA | $924K |
| Prospect Health Access Network, INC. | Chester, PA | $872K |
| Prospect Chartercare Sjhsri, LLC | North Providence, RI | $858K |
| Prospect Health Access Network, INC. | Drexel Hill, PA | $815K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.